Silo Pharma’s Sponsored Research Agreement with Columbia Could Yield a New Alzheimer’s Disease Treatment

Alzheimer’s disease is the sixth leading cause of death in the U.S. and a leading cause of disability and poor health. By 2050, iHealthcareAnalyst projects the number of people suffering from AD will reach 14 million in the U.S. alone. Yet, despite significant investment in clinical trials, the FDA has only approved two types of medications to treat cognitive symptoms.

iHealthcareAnalyst reckons that the global market for AD treatments will reach $25 billion by 2027, representing a staggering 17.5% compound annual growth rate. Moreover, if a therapeutic successfully halts or reverses AD, the potential market could become much larger given that AD care costs exceed $200 billion per year in the U.S. alone.

Most clinical trials focus on the amyloid and tau hypotheses, which blame brain plaques and tau proteins for the disease. Unfortunately, several large Phase III clinical trials focused on these areas have failed. The good news is that there’s a new crop of research focused on alternative therapeutics to halt or slow the progression of the disease.

Let’s take a look at cutting-edge research out of Columbia University and the development-stage biopharmaceutical company with an option to license the results.

Click here to receive investor information and corporate updates

Combination Therapeutics with Ketamine

Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on psychedelic therapeutics, recently entered a sponsored research agreement with Columbia University that could revolutionize the treatment of Alzheimer’s disease and other diseases related to memory loss or cognitive aging processes.

Dr. Christine Ann Denny, Associate Professor of Clinical Neurobiological at Columbia University’s Irving Medical Center, and her team are researching the molecular mechanisms underlying learning and memory. In particular, the team is pioneering research into whether drug combinations that incorporate ketamine might halt or reverse AD and related diseases.

Dr. Denny at her research lab at Columbia University. Source: Columbia University

Under the terms of the sponsored research agreement, Silo Pharma has an option to license certain assets that are currently under development, including Alzheimer’s disease-related inventions. With Big Pharma pouring billions into clinical trials in the space, a successful research outcome could create tremendous value for shareholders.

Following in Spravato’s Footsteps

Ketamine has become a breakthrough treatment for depression and suicidal ideations seemingly overnight. For example, Spravato (esketamine) became the first approved medicine to mitigate depressive symptoms within 24 hours. By comparison, conventional antidepressants take days or weeks to take effect with mixed results.

In the same way, ketamine-based therapeutics could revolutionize Alzheimer’s disease treatments. Memantine, a non-competitive NMDA receptor agonist with a similar pharmacological profile to ketamine, is already one of the most prescribed and investigated drugs for AD patients. However, ketamine has been largely ignored despite its unique potential to treat AD.

Click here to receive investor information and corporate updates

For example, memantine exhibits some antidepressant effects, but it has failed to produce the rapid antidepressant effect of ketamine. As a result, it stands to reason that ketamine’s antidepressant and procognitive effects aren’t entirely shared with memantine. Indeed, researchers point out several pathways that ketamine uniquely employs to combat AD, potentially enhancing treatments.

Looking Ahead

Alzheimer’s disease is a massive problem affecting populations worldwide, making it an enormous multi-billion dollar market.

Silo Pharma Inc.’s (OTCQB: SILO) recent sponsored research agreement with Columbia University targeting AD could be transformative for shareholders. If successful, the company has the option to acquire a new class of blockbuster drugs developed by the Columbia University team.

In addition to its AD research, the company has two drug candidates, two homing peptides for CNS and arthritis/inflammation, as well as two topical psychedelics with patented Zpod technology. With diversification across multiple medical conditions, shareholders benefit from greater diversification and long-term upside potential.

Learn more by visiting the company’s website or downloading their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.